ABCG2 and cancer: This can be achieved via transport from drug-resistant cancer cells to their drug-sensitive counterparts of functional plasma membrane transporter proteins including P-glycoprotein (P-gp), breast cancer resistance protein (BCRP) [76], and multidrug resistance-associated protein 1 (MRP1) [77], or resistance-associated miRNAs [78].